



Decision Dx
▶ Melanoma

Patient Resource Guide

Understanding your risk after
cutaneous melanoma diagnosis



What is melanoma?

Melanoma is one of the three most common types of skin cancer.^{1,2} While some people are at a higher risk than others, anyone can get melanoma.

What is DecisionDx-Melanoma?

DecisionDx-Melanoma is a gene expression profiling (GEP) test that looks at your tumor biology to predict the risk of your melanoma spreading or coming back.

The DecisionDx-Melanoma test uses a small sample from the melanoma biopsy that your provider has already taken and it measures the activity of 31 genes that are related to melanoma growth. Measuring the tumor's genetic expression profile tells if the cancer is behaving aggressively or not. This information can give you a clearer picture of your prognosis and help you and your care team make personalized management decisions.



What do the results mean?

The test results provide you and your healthcare provider with information to guide your care, including:

1

Class Result & GEP Score

A risk-stratification class according to your tumor biology.



Class 1A
Lowest risk



Class 1B/2A
Increased risk



Class 2B
Highest risk

2



Individualized Risk of Recurrence

Personalized risk estimates of your cancer coming back or spreading within the next 5-years

3



Individual Risk of Sentinel Lymph Node Positivity

Personalized risk estimate for how likely you are to have a positive sentinel lymph node biopsy



The results can guide:



Sentinel lymph node biopsy (SLNB) procedure decisions



Frequency of follow-up appointments with your healthcare provider



Additional visits with other specialties (referrals)



Other escalations or de-escalations of your treatment plan including advanced imaging

For more information, visit:
[mymelanoma.com](https://www.mymelanoma.com)

Our testing process

Getting the DecisionDx-Melanoma test is simple. Since the test sample is taken from your original biopsy or surgery, there is no need for another procedure or blood draw. Once completed, the test results are sent directly to your healthcare professional and they will discuss the results and next steps with you.

How is the test paid for?

Castle Biosciences is committed to providing high quality molecular testing to all patients. We do not want financial concerns to be a barrier to patients accessing critical healthcare information.

We will work with all insurance providers, including Medicare, Medicaid, commercial insurers, and Veterans Affairs (VA), to secure payment coverage for our testing.

For those who may need additional assistance with their Castle test, we offer a comprehensive patient assistance program to all patients. If you have any questions, please contact us by calling **866-788-9007, option 3** or emailing **reimbursement@castlebiosciences.com**.

The leader in melanoma prognostic testing

1

the only melanoma prognostic test shown to be associated with improved patient survival^{3,9}

Medicare

covered by Medicare and multiple private insurers

150,000+

patients tested*

1 in 2

patients tested had change in management based on their DecisionDx-Melanoma results⁴⁻⁸

10,000+

patients studied in more than 50 publications, including a collaboration with the National Cancer Institute*

1. National Cancer Institute. Skin Cancer (Including Melanoma) – Patient Version.
2. Centers for Disease Control and Prevention. Basic Information About Skin Cancer.
3. Bailey et al. *JCO PO*. 2023.
4. Dillon et al. *CMRO*. 2022.
5. Berger et al. *CMRO*. 2016.
6. Dillon et al. *SKIN J Cutan Med*. 2018.
7. Farberg et al. *J Drugs Derm*. 2017.
8. Schuitevoerder et al. *J Drugs Derm*. 2018.
9. Dhillon et al. *Archives of Derm Research*. 2023.

*As of December 2023

C/STLE
BIOSCIENCES

©2024 Castle Biosciences Inc.
DecisionDx® Melanoma is a trademark
of Castle Biosciences Inc.
DDXCM-002v4-032024